2352 related articles for article (PubMed ID: 15447678)
41. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.
Schell H; Hasegawa T; Neumann M; Kahle PJ
Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424
[TBL] [Abstract][Full Text] [Related]
42. Genetic contributions to Parkinson's disease.
Huang Y; Cheung L; Rowe D; Halliday G
Brain Res Brain Res Rev; 2004 Aug; 46(1):44-70. PubMed ID: 15297154
[TBL] [Abstract][Full Text] [Related]
43. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?
Chu Y; Kordower JH
Neurobiol Dis; 2007 Jan; 25(1):134-49. PubMed ID: 17055279
[TBL] [Abstract][Full Text] [Related]
44. Viral vector-mediated overexpression of α-synuclein as a progressive model of Parkinson's disease.
Ulusoy A; Decressac M; Kirik D; Björklund A
Prog Brain Res; 2010; 184():89-111. PubMed ID: 20887871
[TBL] [Abstract][Full Text] [Related]
45. Neurofilament mRNA is reduced in Parkinson's disease substantia nigra pars compacta neurons.
Hill WD; Arai M; Cohen JA; Trojanowski JQ
J Comp Neurol; 1993 Mar; 329(3):328-36. PubMed ID: 8459049
[TBL] [Abstract][Full Text] [Related]
46. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.
Wakamatsu M; Ishii A; Iwata S; Sakagami J; Ukai Y; Ono M; Kanbe D; Muramatsu S; Kobayashi K; Iwatsubo T; Yoshimoto M
Neurobiol Aging; 2008 Apr; 29(4):574-85. PubMed ID: 17174013
[TBL] [Abstract][Full Text] [Related]
47. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.
Conway KA; Rochet JC; Bieganski RM; Lansbury PT
Science; 2001 Nov; 294(5545):1346-9. PubMed ID: 11701929
[TBL] [Abstract][Full Text] [Related]
48. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
[TBL] [Abstract][Full Text] [Related]
49. Clusterin/apolipoprotein J is associated with cortical Lewy bodies: immunohistochemical study in cases with alpha-synucleinopathies.
Sasaki K; Doh-ura K; Wakisaka Y; Iwaki T
Acta Neuropathol; 2002 Sep; 104(3):225-30. PubMed ID: 12172907
[TBL] [Abstract][Full Text] [Related]
50. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.
Sidhu A; Wersinger C; Vernier P
FEBS Lett; 2004 May; 565(1-3):1-5. PubMed ID: 15135042
[TBL] [Abstract][Full Text] [Related]
51. A stable proportion of Lewy body bearing neurons in the substantia nigra suggests a model in which the Lewy body causes neuronal death.
Greffard S; Verny M; Bonnet AM; Seilhean D; Hauw JJ; Duyckaerts C
Neurobiol Aging; 2010 Jan; 31(1):99-103. PubMed ID: 18457903
[TBL] [Abstract][Full Text] [Related]
52. Nigral burden of alpha-synuclein correlates with striatal dopamine deficit.
Kovacs GG; Milenkovic IJ; Preusser M; Budka H
Mov Disord; 2008 Aug; 23(11):1608-12. PubMed ID: 18649394
[TBL] [Abstract][Full Text] [Related]
53. The role of Ser129 phosphorylation of α-synuclein in neurodegeneration of Parkinson's disease: a review of in vivo models.
Sato H; Kato T; Arawaka S
Rev Neurosci; 2013; 24(2):115-23. PubMed ID: 23314528
[TBL] [Abstract][Full Text] [Related]
54. Controversy: is Parkinson's disease a single disease entity? Yes.
Takahashi H; Wakabayashi K
Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S31-7. PubMed ID: 15885626
[TBL] [Abstract][Full Text] [Related]
55. G protein-coupled receptor kinase 5, overexpressed in the alpha-synuclein up-regulation model of Parkinson's disease, regulates bcl-2 expression.
Liu P; Wang X; Gao N; Zhu H; Dai X; Xu Y; Ma C; Huang L; Liu Y; Qin C
Brain Res; 2010 Jan; 1307():134-41. PubMed ID: 19852948
[TBL] [Abstract][Full Text] [Related]
56. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates.
Purisai MG; McCormack AL; Langston WJ; Johnston LC; Di Monte DA
Neurobiol Dis; 2005 Dec; 20(3):898-906. PubMed ID: 16006134
[TBL] [Abstract][Full Text] [Related]
57. Development and characterisation of a novel rat model of Parkinson's disease induced by sequential intranigral administration of AAV-α-synuclein and the pesticide, rotenone.
Mulcahy P; O'Doherty A; Paucard A; O'Brien T; Kirik D; Dowd E
Neuroscience; 2012 Feb; 203():170-9. PubMed ID: 22198020
[TBL] [Abstract][Full Text] [Related]
58. Interaction of alpha-synuclein and dopamine metabolites in the pathogenesis of Parkinson's disease: a case for the selective vulnerability of the substantia nigra.
Galvin JE
Acta Neuropathol; 2006 Aug; 112(2):115-26. PubMed ID: 16791599
[TBL] [Abstract][Full Text] [Related]
59. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
Novikova L; Garris BL; Garris DR; Lau YS
Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
[TBL] [Abstract][Full Text] [Related]
60. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
Decressac M; Mattsson B; Björklund A
Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]